Introduction
Effective radioprotective agents have been sought since the advent of the atomic age. The initial impetus for the search was to protect human populations during nuclear warfare. Since then, many naturally-occurring and synthetic agents have been identified. Much of the interest in radioprotectors has now shifted to clinical settings where these agents are used as cytoprotectors in cancer patients undergoing chemo-and/or radiotherapy. The hope is that these agents may also reduce the incidence of secondary, treatment induced malignancies in cancer patients.
/V-(2-mercaptoethyl)-1,3-diaminopropane (WR-1065*) is the in vitro active species of the well-characterized radioprotector WR-2721, which requires in vivo metabolic activation. There is considerable interest in WR-2721 and WR-1065 because these agents appear preferentially to protect normal rather than neoplastic tissues against the deleterious effects of alkylating agents or ionizing radiations (1,2). These and other thiolcontaining compounds have been shown to exhibit antitransforming (3), anticlastogenic (4), anticarcinogenic (5) and antimutagenic (6) (7) (8) properties in mammalian cells.
In murine studies, WR-2721 increases the lifespan and decreases the incidence of lymphocytic lymphomas in animals receiving neutron or y-irradiations (9,10). Decreases in hypoxanthine-guanine phosphoribosyl transferase (hprt) mutant frequencies determined in splenic lymphocytes were
•Abbreviations: WR-1065, A/-(2-mercaptoethyl)-l,3-diaminopropane; hprt, hypoxanthine-guanine phosphoribosyl transferase; MNC, mononuclear cell; PHA, phytohemagglutinin; CE, cloning efficiencies.
© Oxford University Press also observed (11). Increases in cell survival in vitro in Chinese hamster cell lines have been observed only if the aminothiol, WR-1065, is administered prior to irradiation; but hprt mutations decrease regardless of the time of administration of the aminothiol (6, 12) . As the latter are continuously replicating cells, there is controversy as to the mechanism of the protection by the aminothiols, especially the role of alterations of the cell cycle. This relates to the relevance of these in vitro observations for in vivo events in quiescent cells.
Somatic mutations in human peripheral blood T-lymphocytes, arising in the hprt reporter gene, are conveniently selected by resistance to the purine analog 6-thioguanine. This is the basis of a cloning assay for these events arising in vitro or in vivo (13) (14) (15) . Although hprt mutations are not mutations in cancer genes, events here should mimic what is occurring elsewhere in the genome. O'Neill et al. (15) , assaying for in vitro mutations, showed that hprt mutant frequencies increase in GQ T-lymphocytes exposed to 3 Gy
137
Cs external beam irradiation, and that the molecular spectrum is characterized by gross structural alterations of the gene, i.e. translocations and total and partial deletions. Later, Nicklas et al. (16) obtained essentially the same results in vivo in patients receiving radioimmunoglobulin therapy (RIT) by demonstrating both an increase in T-lymphocyte hprt mutant frequencies and an increase in the fraction of mutations containing gross structural alterations of the gene, primarily total deletions. Thus, hprt mutations in GQ T-lymphocytes resulting from either in vitro or in vivo ionizing radiation exposures are large-scale events. Such gross structural alterations comprise only 15% of the in vivo background at this locus in unexposed normal individuals. Point mutations and small deletions/insertions, which escape Southern blot detection, comprise the remaining 85% of the background or 'spontaneous' in vivo hprt mutations (17) (18) (19) (20) (21) .
The objective of the current study was to determine if WR-1065 is antimutagenic in vitro in human G o T-lymphocytes following external beam y-irradiation. The response of G o Tlymphocytes in vitro should closely mimic the response of these same cells in vivo when these or similar radioprotective agents are administered in conjunction with radiation or chemical therapies in cancer patients. We found that WR-1065 does significantly protect human T-lymphocytes from radiationinduced hprt mutations. This indicates that assessing for in vivo mutations of this gene in T-lymphocytes can be used for monitoring radioprotective regimens offered to cancer patients.
Materials and methods

Determination of radiation induced cytotoxicity
Peripheral blood was obtained from healthy donors after receiving informed consent and the mononuclear cell (MNC) layer was isolated by Histopaque (Sigma) separation. The MNCs were washed in Saline G, resuspended at 2 X 10* cells/ml in medium RPMI 1640 (VWR) and divided into five tubes: (i) control; (ii) treatment with 4 mM WR-1065 alone; (iii) treatment with 3 Gy 137 Cs y-irradiation alone; (iv) and (v) treatment with both 3 Gy yirradiation and 4 mM WR-1065 30 min before or 3 h after the irradiation, respectively.
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A working solution of WR-1065 was prepared in phosphate-buffered saline and filter sterilized immediately before use. All tubes were incubated at 37°C for 3 h following their final treatment, either irradiation or WR-1065. For all except the tubes receiving WR-1065 after irradiation, the cells were incubated for 3 h post-irradiation. For the tubes receiving WR-1065 last, the cells were incubated for 6 h post-irradiation. An aliquot of 1 |ig/ml phytohemagglutinin (PHA; Burroughs Wellcome) was then added to the tubes followed by an additional 36-40 h incubation. Cells were then inoculated at 1, 2 or 5 cells/ well into microtiter plates to determine cytotoxicity.
Microtiter plates were scored for cell growth in wells by inverted phase microscopy at 10 days post-inoculation. Cloning efficiencies (CE) were calculated using the Poisson relationshp P o = e~*, where P o is the fraction of no growth wells and x the average number of clonable cells/well. CE is defined as x/n, where n is the number of cells originally inoculated into the wells. Relative survivals were determined as the CEs in the various treated tubes related to control tubes. Mean relative survivals were determined in eight independent experiments using T-lymphocytes isolated from three different normal individuals.
Cloning assay for hprt mutants
The hprt cloning assay was used to determine mutant frequencies after various intervals of exponential cell growth to allow for expression (22) . Briefly, cells from each tube were subcultured at 2 X 10* cells/ml at 3-day intervals in growth medium consisting of 20% medium HL-1 (Sigma), 5% calf bovine serum (CBS; Hyclone), 75% medium RPMI 1640 (VWR), a source of interleukin-2 (IL-2; supernatant of MNCs cultured with IL-2 for lymphokine activated killer cell therapy) and irradiated Aprr-lymphoblastoid accessory cells. Each subculture passaged 20 X 10 6 cells except for the first for cells treated with WR-1065 and/or y-irradiation, when additional cells predetermined by relative survivals were passaged to compensate for cell killing. After growth for 2, 5 or 8 days, cells were washed, diluted in appropriate medium and inoculated into the wells of microtiter plates at 10 4 cells/well for mutant selection and 1, 2 or 5 cells/well to determine CE. Selection medium contained 10 mM 6-thioguanine (TG; Sigma), 0.25 ^ml PHA and 10 4 irradiated accessory cells in the HL-1 and CBS supplemented medium RPMI 1640. All wells were fed with the appropriate medium at 3 days and wells were scored for growth by inverted phase-contrast microscopy at 10-15 days. Mutant frequencies were calculated as the ratio of the CE in the presence of the CE in the absence of selection (22, 23) .
Assessment of cell cycle effects
To investigate whether WR-1065 perturbs cell-cycle progression, cell-cycle analyses were performed by flow cytometry. Briefly, MNCs were isolated, treated, and activated as described above. After PHA stimulation for 40 h, cells were harvested and resuspended in sample buffer (20% glucose in Ca 2+ -and Mg 2+ -free phosphate-buffered saline). Cells were then washed in sample buffer twice, each time being centnfuged for 10 min at 400 g at 4°C. The cells were resuspended in sample buffer and counted on a hemocytometer. A total of 1 X 10 6 cells from each treatment were fixed in 70% ethanol overnight. Cells were stained the next morning using propidium iodide stain [50 Hg/ml propidium iodide stock solution (Sigma) and 100 U/ml Kunitz units RNase A (Sigma) in 10 ml sample buffer]. DNA content was analyzed by a Coulter Counter Elite flow cytometer.
Statistical analysis
The data were analyzed as two sets: one for WR-1065 added 30 min prior to irradiation, and one for WR-1065 added 3 h post-irradiation. Each set consisted of control, WR-1065 only, and 3 Gy l37 Cs-irradiation only, as well as the WR-1065 treatment pre-or post-irradiation. The mutant frequencies for each set were compared using a multiple companson analysis of variance (ANOVA) test.
Results
Protection from radiation induced cytotoxicity
Cytotoxicity was determined in eight independent experiments using T-lymphocytes isolated from three different normal individuals. Mean cell survivals (relative CE) following in vitro treatments with 4 mM WR-1065 alone, 3 Gy y-irradiation alone, WR-1065 followed by irradiation after 30 min, or irradiation followed in 3 h by WR-1065 are shown in (data not shown). Three Gy y-irradiation gave the expected level of cytotoxicity, reducing the mean relative CE to 22%, as reported previously (22) . However, pretreatment of cells with WR-1065, which remained in the medium during irradiation, significantly protected the irradiated cells, increasing the mean relative CE to 64%. There was no protective effect of WR-1065 when it was administered 3 h after irradiation, indicating that the radioprotector had to be present before and/or during the l37 Cs exposure.
Protection from radiation mutagenesis
Mutagenicity was assessed in four independent experiments using T-lymphocytes isolated from three different normal individuals. Phenotypic expression was achieved by subculturing treated cells and plating them at 3-day intervals for mutation detection. Optimum expression occurred at 8 days, with no increases in mutant frequency at later time points (data not shown). The initial series of experiments assessed the antimutagenic effects of 4 mM WR-1065 administered 30 min before 3 Gy Y-irradiation (Figure 2 ). The radioprotector alone had no mutagenic effect while irradiation alone increased mutant frequencies 7-fold over control. WR-1065 administered 30 min prior to and present during irradiation, however, reduced the mutant frequencies of the l37 Cs-treated cells to background levels on both day 5 and day 8 of expression. This reduction was statistically significant at the day 8 time point (P < 0.01) (Figure 2 and Table I) .
A second series of experiments was conducted to determine if this same dose of WR-1065 was antimutagenic when administered to cells 3 h after rather than 30 min before the 3 Gy y-irradiation and, therefore, not present during the latter treatment. As shown in Figure 3 , WR-1065 again showed no mutagenic effects while irradiation alone again increased mutant frequencies, this time 10-fold over control. When WR-1065 was given 3 h following irradiation, mutant frequencies again were reduced on both day 5 and day 8 of expression in the irradiated cells. However, results were more variable in this series of experiments and, while the level of mutant reduction at the day 8 time point was 74%, this did not reach statistical significance (P > 0.05) (Figure 3 , Table I ).
Cell cycle effects of WR-1065
The effect of WR-1065 on retarding cell cycle progression of PHA stimulated G o T-lymphocytes was tested ( Figure 4 and Table II substantially retarded the cell cycle progression of human Tlymphocytes or the initiation of the mitogenic response. However, this retardation did not interfere with cell division to allow phenotypic expression. Cumulative growth curves (23) of cells subcultured for expression show that cell growth was not inhibited ( Figure 5 ).
Discussion
The current study demonstrates unequivocally that the aminothiol WR-1065 protects human GQ T-lymphocytes from ionizing radiation-induced cytotoxicity and gene mutation when the agent is present before and during the irradiation. Furthermore, there is a strong suggestion that WR-1065 is antimutagenic in these cells even when its administration is postponed until 3 h after the l37 Cs treatment. WR-1065 has been shown to be antimutagenic alone, without increasing cell lethality (24) . Our observations extend the reports in the literature to a cell type that is not replicating (G o ) during the WR-1065 and irradiation treatments, and to a somatic gene mutation endpoint for monitoring the antimutagenic effect of this aminothiol.
The final concentration of 4 mM WR-1065 used here is that 2650 routinely used for in vitro studies because it is non-toxic and produces maximal protection. Lower serum levels, however, are probably achieved by the usual doses of these agents given to cancer patients. Cells concentrate the thiol and disulfide forms of the aminothiol so that serum/medium concentrations cannot be directly compared with intracellular concentrations. The disulfide form is maximally concentrated in cells via a polyamine transport system at concentrations achieved in the clinic (25) . The in vitro concentration of WR-1065 used in our studies is similar to in vivo concentrations of endogenous polyamines.
The intra-individual variability in mutant frequency values encountered in these studies has several causes (26) . The blood samples were taken at different times and thus, the values in part reflect temporal month to month variation in an individual's background. In vitro experiments performed as described have multiple Poisson sampling errors due to the multiple subcultures. An attempt was made to minimize these by passing 20 X 10 6 cells per subculture so that, on average, 50-100 mutants should have been present at each subculture. It is all the more significant, therefore, that antimutagen effects of approximately the same magnitude were seen even with this variability in the background.
Several mechanisms have been postulated to explain the antimutagenic radioprotective effects of aminothiols such as WR-2721 and WR-1065. These include free radical scavenging, oxygen depletion, chemical DNA repair via hydrogen atom donation and enhanced enzymatic DNA repair (27, 28) . Although the first of these is attractive, several observations argue that this cannot be the only mechanism of action of these agents. For example, WR-1065 affords greater protection against ionizing radiation-induced chromosome damage than does the highly efficient OH radical scavenger dimethyl sulfoxide (29) . Also, the antimutagenic activity of WR-1065 when administered after ionizing radiation is not consistent with free radical scavenging or oxygen depletion as the only mechanisms of action. Free radical species have short lifetimes, i.e. ~10~5 s (30) , while oxygen depletion by WR-1065 cannot be a mechanism since the aminothiol is not present until after the mutagenic irradiation.
It is likely that the aminothiols exert at least some of their radioprotective effects by influencing DNA repair. These compounds are known to inhibit both DNA synthesis (28) and cell cycle progression in exponentially growing cells in culture (31) . WR-1065, in particular, perturbs cell cycle progression, resulting in accumulations of S and G2 (31, 32) . Such delays may increase the time available for repair of DNA lesions before they are converted to irreversible mutations. Consistent with this is the finding of Grdina and Sigdestad (33) that WR-1065 affords the greatest protection for cells in G] as opposed to other stages of the cell cycle. The longer the cell-cycle delay, the higher the probability of effective repair. The lymphocytes in this study were in G o at the time of WR-1065 treatment, and their PHA-induced progression into the first S-phase was retarded. This effect of WR-1065 to retard entry probably enhanced the probability of effective repair. It might be argued that the WR-1065 post-irradiation cultures extended the time for repair by 3 h simply by experimental design, thereby also allowing increased time for DNA repair. This, however, could not have accounted for the reduced mutagenicity in these cultures because: (i) the time for PHA stimulation to the initial S-phase in normal Tlymphocytes is ~24-28 h (34-38), which is > 10 times longer than this additional incubation interval; (ii) these cultures had no reduction in irradiation induced cytotoxicity; and (iii) no differences in cytotoxicity, mutagenicity or antimutagenicity were seen in separate experiments which did not allow an additional 3 h incubation period for these cultures (data not shown).
Studies in DNA repair deficient organisms support the involvement of the endogenous DNA repair enzyme systems in radioprotection. Cysteamine, a compound similar to WR-1065, protects wild-type Escherichia coli but not strains defective in the rec system from ionizing radiation induced damage (27, 39) . Similarly, X-ray repair deficient rad~ mutants of Saccharomyces cerevisiae were not protected by cysteamine from such damage while wild-type yeast were protected (40) . In mammalian cells, WR-1065 did not protect against the lethal effects of ionizing radiation in the DNA repair deficient xrs-5 CHO cell line (41) .
Other observations relate to the mechanisms responsible for the radioprotective effects of the aminothiols. WR-1065 produces a conformational change in DNA, which affects the process of normal DNA synthesis and strand-break rejoining, slowing it and allowing a longer time for accurate repair (42, 43) . More recently, WR-1065 was found by Grdina et al. (44) to reduce topoisomerase Ha activity in mammalian cells by an average of 50%. However, topoisomerase Ha activity is greatest in G 2 /M and the cell-cycle delay seen here was earlier than G 2 . Therefore, although delay by topoisomerase Ha following S-phase may further increase time for DNA repair, other DNA repair and replication mechanisms must be involved. Although the precise mechanisms of aminothiol radioprotection have not been identified, the majority of studies thus far strongly implicate the involvement of cell cycle enzymes and endogenous DNA repair enzyme systems in addition to free radical scavenging and hydrogen donation.
The current study was undertaken to determine if the cloning assay for hprt mutations in T-lymphocytes would be useful for monitoring antimutagenic effects. This T-lymphocyte cloning assay permits study of the same cells in vitro and in vivo. In vitro mutagenicity studies in humans, by assessing the effects of specific manipulations, greatly aid in interpreting results of in vivo studies, where manipulations are rarely possible (15, 16, 45) . As we show here, WR-1065 clearly protects G o T-lymphocytes in vitro from ionizing radiationinduced cytotoxicity and mutagenesis. We report elsewhere that the kind of event specifically eliminated from the mutational spectrum by this aminothiol is that which characterizes ionizing radiation-induced mutations at hprt, i.e. large-scale DNA alterations. Therefore, we have shown that the hprt cloning assay does detect radioprotective effects, and suggest that it can be used to monitor humans for antimutagenicity. The ultimate goal of monitoring will be the reduction or elimination of untoward late effects of therapy, such as treatment-induced malignancies in cancer patients.
